UroGen Pharma Ltd. 8-K

What Happened

• UroGen Pharma Ltd. (filed 8-K on March 2, 2026) and its subsidiary UroGen Pharma, Inc. entered a Loan Agreement on February 26, 2026 with BPCR Limited Partnership and BioPharma Credit Investments V (Master) LP (Collateral Agent: BioPharma Credit PLC). The lenders agreed to provide up to $250.0 million in term loans. The first tranche (Tranche A) of $200.0 million was funded on the Tranche A Closing Date; the borrower may elect to draw a $50.0 million Tranche B no later than June 30, 2027. Proceeds of Tranche A refinance an existing $125.0 million facility and the balance will be used for general corporate and working capital.

Key Details

• Total facility: up to $250.0 million; Tranche A funded $200.0 million on effectiveness, Tranche B $50.0 million optional (election by 6/30/2027).
• Interest: fixed 8.25% per year, payable quarterly in arrears.
• Fees & prepayments: 1.50% funding fee on each tranche at closing; 1.0% exit fee on any principal repaid; makewhole equals interest through the 1st anniversary for early prepayments of a tranche.
• Repayment & security: maturity on the 5th anniversary of Tranche A Closing; principal repaid in four equal quarterly installments beginning in Q1 2030. Obligations guaranteed by the parent (subject to Israeli law limits) and secured by substantially all tangible and intangible assets, including IP.
• Covenants & defaults: customary affirmative and restrictive covenants (e.g., limits on asset sales, additional indebtedness, dividends) but no financial covenants; customary events of default allow lenders to accelerate the loan.

Why It Matters

• Liquidity and refinancing: The funded $200M tranche immediately refinances UroGen’s prior $125M loan and provides additional cash for working capital, which affects near-term liquidity and runway.
• Cost and flexibility: The loan carries a fixed 8.25% rate with fees and prepayment penalties (exit fee and makewhole), and it is secured by most company assets. While there are no financial covenants, the restrictive covenants and security interest could limit strategic flexibility (asset sales, additional debt, dividends) until obligations are repaid or refinanced.
• Repayment timeline: Principal amortization does not begin until 2030, so near-term cash flow impact is limited to interest and fees; however, investors should note the mid-term repayment schedule and the conditions that could trigger acceleration.